Citations

Clear

4206 citation(s) found for "Chen, Yu".

Tregs Require ABCB7 for their Development and Stability 2258259
Zastrow, Alexi, Zhao, Geoffrey , Kim, Eugene, Lehrke, Michael, Rajcula, Matt, Chen, Maggie , Crotts, Sydney, Maniaci, Brandon, Martinez, Kodi, Barnes, Jackson, Carlson, Abigail, Zastrow, Alexi, Lehrke, Michael Jonathan , Rajcula, Matthew, Crotts, Sydney B. , Martinez, Kodi, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.565 Get It

Abstract Introduction The mitochondrial transporter ABCB7 is essential for exporting iron-sulfur (Fe-S) clusters, a function known to be critical in B cells. This study was conducted to investigate the broader, previously unknown roles of ABCB7 in regulating the overall lymphocyte development and homeostasis. Methods The study utilized conditional knockout (cKO) mouse models (CD2-iCre and Mb1-Cre) to create a specific deficiency of ABCB7 in certain immune populations. To determine if the observed effects were due to ABCB7 deletion in myeloid cells, two further models (CD2i-Cre ABCB7 cKO/C/EBPα and CD2-iCre LSL TMT ABCB7 cKO) were developed. The effects of blocking the cytokine G-CSF were also examined to understand its role in the observed myelopoiesis. Results ABCB7 deficiency was found to dramatically impair erythropoiesis while simultaneously driving emergency myelopoiesis. We confirmed that the myeloid expansion was not a direct result of ABCB7 loss in myeloid cells. A significant autoimmune phenotype also developed, characterized by hyperactivated T cells and a sharp decrease in peripheral regulatory T cells (Tregs). This Treg instability was linked to decreased thymic expression of key stability genes (like CD28 and PD-1) and reduced O-GlcNAc modification in T cells, a process crucial for maintaining Treg lineage. Conclusion The findings establish ABCB7 as a pivotal regulator of hematopoietic balance, linking mitochondrial function to both myeloid expansion and Treg stability. Funding Source T32AI170478 Topic Categories Hematopoiesis and Immune System Development (HEM)
Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells, but likely not autoantibodies 2251377
Yu, Yue, Chen, Shiju, Langenfeld, Hannah, Li, Yanfeng, Wang, Panwen , Li, Ying, Markovic, Svetomir, Davis, John, Crowson, C. S., Thanarajasingam, Uma , Zeng, Hu, Zhu, Xingxing , Langenfeld, Hannah E., Markovic, Svetomir, Davis, John M. , Dong, Haidong , Zeng, Hu

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.111 Get It

Abstract Introduction The underlying immunopathogenesis of inflammatory arthritis (IA) immune-related adverse event (irAE) remains obscure. Unlike rheumatoid arthritis (RA), where autoantibodies and B cell dysfunction are central features, the contribution of humoral immunity to IA-irAE is unclear. Methods Here, we performed immunophenotyping of peripheral blood from IA-irAE patients, and compared them with seronegative RA patients, ICI-treated patients without irAE, and healthy controls. Results IA-irAE was marked with increased cytotoxic gene expression and metabolic activation in T cells, and reduced CXCR3 and CCR6 expression in CD4+ T cells. Contrary to seronegative RA, IA-irAE patients displayed no significant elevation in autoantibody levels or atypical CD11c+CD21⁻ B cells. IA-irAE was further characterized by elevated levels of IL-6, IL-12, and type I IFN, which correlated with the T cell activation phenotypes. Conclusion Altogether, our findings define IA-irAE as a disease with certain immunological features distinctive from RA, representing a potentially T cell driven, autoantibody-independent autoimmunity. These results offer insights into immune tolerance breakdown and therapeutic targeting in irAEs. Funding Source National Institute of Arthritis and Musculoskeletal and Skin Diseases Mark E. and Mary A. Davis Initiative in Rheumatoid Arthritis Research Mayo Foundation for Medical Education and Research Topic Categories Basic Autoimmunity (BA)
Abstract Fri086: CD38 NADase Suppresses Sulfite Oxidase (SUOX) and Activates Reverse Complex V to Promote Metabolic Remodeling in Endothelial Cells (ECs) Under Disturbed Flow
Ko, Kyung Ae , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Rivera, Luis Antonio, KIM, JUNG HYUN, Ostos-Mendoza, Kelia, Deswal, Anita, Pathania, Rajneesh , Morrell, Craig, Chini, Eduardo N. , Martin, James, Hamilton, Dale, Seeley, Erin, Burks, Jared, Brookes, Paul, LE, NHAT TU, Abe, Junichi, Kotla, Sivareddy , Lee, Jonghae , Chen, Weiqing , Hoang, O.N. , Zhang, Aijun , Imanishi, Masaki , Mendoza, Keila Carolina Ostos , Morrell, Craig , Shen, Ying , Hamilton, Dale J. , Burks, Jared K , Wang, Guangyu

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | July 28, 2026 | Volume: 46 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.46.suppl_1.fri086 Get It

Introduction: Atherosclerotic lesions preferentially form in arterial regions exposed to disturbed flow (DF), where ECs exhibit mitochondrial (mt) dysfunction, metabolic reprogramming, and senescence. Hippo pathway kinases LATS1/2 maintain EC homeostasis, but how DF–mediated LATS1/2 suppression drives EC metabolic remodeling remains unclear. Hypothesis: We propose that DF activates CD38, leading to mt dysfunction and metabolic reprogramming that promotes EC senescence and aberrant proliferation by LATS1/2 inhibition. Methods: EC-specific Lats1/2 knockout mice were generated using tamoxifen-inducible Cre systems, and DF was induced by partial carotid ligation. Murine and human plaques were analyzed using COMET™ immunofluorescence, and spatial metabolomics. Bioenergetic profiling included Seahorse XF analysis, 13 C-glucose/ 13 C-glutamine tracing, and pharmacologic modulation of CD38, mtROS, and ATP synthase. Results: Complete Lats1/2 deletion caused fatal edema and vascular leakage, while partial loss produced fragile, highly neovascularized plaques. Spatial proteomics revealed a CD38-driven senescence-associated stemness (SAS) phenotype under LATS1/2 deficiency. Metabolomics showed sulfite and taurine accumulation, consistent with SUOX deficiency. Mechanistically, CD38 suppressed SUOX, induced Complex V reverse-mode , increased succinate flux, and accelerated ATP consumption. Despite ATP depletion, glutamate metabolism and TCA cycle flux were enhanced, sustaining EC proliferation under energetic stress. LATS1/2 knockdown reduced mt respiratory capacity (lower OCR peak) without significantly increasing glycolysis, and DF suppressed both OCR and ECAR, indicating impaired energy metabolism under pathological shear stress. CD38 inhibition restored mt respiration and glycolytic capacity by preserving NAD, and rescuing LATS1/2 and DF-mediated defects. Blocking reverse-mode Complex V reduced DF- and LATS1/2-dependent EC senescence and proliferation. Conclusion: Complete LATS1/2 deletion causes fatal vascular leakage, while partial loss drives plaque formation with fragile neovessels through a CD38-dependent SAS phenotype. CD38 suppresses SUOX, induces Complex V reverse-mode , increases succinate flux, and accelerates ATP consumption, enabling EC proliferation despite energy stress. DF and LATS1/2 loss impair mt and glycolytic function, whereas CD38 inhibition restores mt respiration and reduces EC senescence and proliferation to prevent atherothrombosis in DF regions.
The Proposed Bone Post-Arterial Type R Capillaries Resolve into Venous and Fatty Acid-Handling Endothelial Cells
Jain, Sanyam , Joseph, Jessy Davina, Liu, Hanyu , Bhowmick, Nainita, Yang, Yang, Mundapat, Siddharth Nishant, Glaviano, Antonino , Chandra, Abhishek , Dalan, Rinkoo , Chen, Junyu , Risbud, Makarand V. , Bözec, Aline , Roy, Nainita , Machan, Radek , Chandra, Abhishek , Dalan, Rinkoo , Chen, Junyu , Verma, Navin Kumar , Cohen-Solal, Martine , Risbud, Makarand V , Bozec, Aline , Kusumbe, Anjali P , Joseph, Jessy D

Mayo Clinic

No container title available | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.27.741009 | PMID 42619693 Get It

Abstract Endothelial specialization is increasingly recognized as a fundamental regulator of tissue homeostasis, yet the cellular diversity of the skeletal vasculature remains incompletely resolved. Here, we integrate large-scale single-cell transcriptomics, cross-tissue comparisons, and imaging to comprehensively define endothelial heterogeneity across the skeleton. Our analyses demonstrate that the proposed post- arterial “type R” endothelial population is not a distinct endothelial subtype but instead comprises canonical venous endothelial cells and fatty acid-handling endothelial state. RNA velocity supports a venous continuum, while the proposed type R markers FMO2, and AQP7 lack both endothelial and skeletal specificity. The fatty acid-handling endothelial state, characterized by Lpl and Cd36 is conserved across multiple skeletal sites and non-skeletal tissues, indicating a general endothelial metabolic programme. Within bone, this endothelial state expands following high-fat diet and is suppressed during injury. Together, these findings redefine skeletal endothelial heterogeneity and establish the proposed type R population as part of a venous continuum.
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
McKay, Rana R. , Ballman, Karla V. , Atherton, Pamela J. , Ajmera, Archana , Baghdadi, Tareq Al, Baumann, Brian C. , Beltran, Himisha , Berg, Stephanie , Chen, Ronald C. , Choudhury, Atish D. , Jacene, Heather A. , Kilari, Deepak , Kwok, Young , Swami, Umang , Tan, Alan , Yang, Yuanquan , Zhang, Tian , Galsky, Matthew D. , George, Daniel J. , Baghdadi, Tareq Al , Cole, Suzanne , Jacene, Heather A , Lang, Joshua M , Kilari, Deepak , Kwok, Young , McGregor, Bradley , Morris, Michael J , Parikh, Mamta , Swami, Umang , Tan, Alan , Yang, Yuanquan A , Zhang, Tian , Galsky, Matthew D , Rosenberg, Jonathan E , George, Daniel J , Choueiri, Toni K , Baumann, Brian C , Choudhury, Atish D , Chen, Ronald , Ballman, Karla , Berg, Stephanie A , Cole, Suzanne , Lang, Joshua M. , McGregor, Bradley A. , Morris, Michael J. , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | July 27, 2026 | Volume: 44 | Issue: 24 | Pages: 2341-2352

10.1200/jco-26-01135 | PMID 42507969 Get It

PURPOSE Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223 ) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS This phase II trial enrolled patients with mRCC of any histology with ≥1 BM. Patients were randomly assigned 1:1 to cabozantinib ± radium-223, stratified by osteoclast-targeted therapy (OTT), prior therapy, opioid use, and International mRCC Database Consortium (IMDC) risk. The primary end point was SSE-free survival (SSE-FS). Secondary end points included safety, objective response rate (ORR), progression-free survival, and overall survival (OS). A target of 124 evaluable patients was planned, with a prespecified interim futility analysis at 50% of expected SSE-FS events; the trial would stop if the stratified hazard ratio (sHR) > 1.0. RESULTS The prespecified interim futility analysis was conducted after 90 patients were enrolled and crossed the futility boundary, leading to closure at 98 patients. The final analysis included all 98 patients. Median age was 63 years, 82.7% had clear cell histology, and 79.6% were using an OTT. IMDC risk was favorable (18.4%), intermediate (67.3%), and poor (14.3%). Median follow-up was 13.1 months. Median SSE-FS for cabozantinib with radium-223 versus cabozantinib was 16.7 versus 17.6 months (sHR, 1.46 [90% CI, 0.86 to 2.51]). Median OS was 28.3 versus 19.7 months (sHR, 1.40 [95% CI, 0.70 to 2.79]). ORR was 19.4% versus 25.0% ( P = .78). Grade ≥3 adverse events were similar across arms (69.6% v 75.5%). CONCLUSION Radium-223 did not improve SSE-FS when added to cabozantinib. The combination demonstrated a manageable safety profile.
The NLRC4 Inflammasome Drives Myelodysplastic Syndrome by Linking Epigenetic Reprogramming and Innate Immune Signaling
Chen, Chuan , Bilbao, Daniel , Rostami, Narges , Mas Martin, Gloria

Mayo Clinic

Blood Advances | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020095 | PMID 42498284 Get It

Myelodysplastic syndromes (MDS), which are hematopoietic stem cell malignancies, are often accompanied by signs of chronic inflammation, that can in turn drive the pathogenetic process. The precise mechanisms dysregulating inflammatory and innate immune signaling in MDS hematopoietic stem and progenitor cells (HSPCs) remain under investigation. We report that mice lacking Tet2 developed a hyper-inflammatory state, which can be further fueled by LPS-induced inflammation. This chronic inflammation temporarily promotes the self-renewal and myeloid differentiation of Tet2-deficient HSPCs; however, it ultimately accelerates HSC exhaustion and triggers MDS development in chimeric mouse models. Driving this phenotype was the activation of the NLRC4 inflammasome pathway. Notably, Nlrc4 depletion in Tet2-deficient mice impaired MDS development and improved the survival of these mice. These findings uncover a novel mechanistic basis for the MDS-associated inflammation and provide new targeting opportunities in its management.
First-pass aspiration versus stent retriever thrombectomy: machine learning study of treatment effect heterogeneity
Chen, Huanwen , Isidor, Julio , Schirmer, Clemens, Ernst, Marielle , Rai, Ansaar, Jabbour, Pascal , Abecassis, Isaac Josh , Grossberg, Jonathan A , Alawieh, Ali, Khanna, Omaditya, Starke, Robert M, Psychogios, Marios-Nikos, Siddiqui, Fazeel, Samaniego, E, Goyal, Nitin, Ezzeldin, Mohamad , Dye, Justin, Alcedo, Rodolfo, Cerejo, Russell , Luther, Evan, Romano, Daniele G, Tanweer, Omar, Mascitelli, Justin, Cuellar, Hugo H, Chalouhi, Nohra , Limaye, Kaustubh, Kellogg, Ryan, Brinjikji, Waleed, Chowdhry, Shakeel , Spiotta, Alejandro M , Kan, Peter , Jabbour, Pascal , Abecassis, Isaac Josh , Grossberg, Jonathan A , Navia, Pedro , Ezzeldin, Mohamad , Alaraj, Ali , Yoshimura, Shinichi , Fiorella, David , Fragata, Isabel , Mokin, Maxim , Matouk, Charles , Chowdhry, Shakeel A , Altschul, David J , Ogilvy, Christopher S , Levitt, Michael R , Grandhi, Ramesh , Spiotta, Alejandro M , Kan, Peter , Kim, Jae‐Joong , Rai, Ansaar , Jabbour, Pascal , Navía, Pedro , Starke, Robert M. , Psychogios, Marios‐Nikos , Goyal, Nitin , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi , Almallouhi, Eyad , Fiorella, David , Romano, Daniele Giuseppe , Tanweer, Omar , Fragata, Isabel , Mascitelli, Justin R , Limaye, Kaustubh , Matouk, Charles , Kellogg, Ryan Thomson , Brinjikji, Waleed , Altschul, David , Ogilvy, Christopher S. , Levitt, Michael R. , Grandhi, Ramesh , Chen, Huanwen

Mayo Clinic

Journal of NeuroInterventional Surgery | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: jnis-2026-025615

10.1136/jnis-2026-025615 | PMID 42498630 Get It

Background Randomized trials have shown equivocal outcomes between a direct aspiration as first-pass technique (ADAPT) and stent retriever (SR) stroke thrombectomy, yet whether specific patient subgroups benefit differentially from one technique over the other remains unknown. Methods In this retrospective multicenter cohort study, patients with large vessel occlusion were included, and those who underwent ADAPT versus SR first-pass thrombectomy (either as standalone or combined with aspiration) were compared. The primary outcome was a composite of first-pass effect (FPE, modified Thrombolysis In Cerebral Infarction (mTICI) 2c or better with one attempt) with no symptomatic intracranial hemorrhage (sICH). A causal forest model was used to estimate the conditional average treatment effect (CATE) for each patient, with larger CATEs indicating that ADAPT is expected to be more advantageous. Patients were stratified by CATEs, and outcomes were compared between treatment groups. Results Among 6700 included patients, ADAPT (n=3695, 55%) was associated with a higher rate of FPE with no sICH (39.9% vs 26.9%; adjusted OR (aOR) 2.07, 95% CI 1.77 to 2.41, P<0.001). The causal forest identified significant treatment effect heterogeneity (interaction P<0.001), where ADAPT was more advantageous in more recent years and among patients with M1 occlusions presenting in earlier time windows. Low-CATE patients showed no statistically significant difference between techniques (aOR 0.91, 95% CI 0.57 to 1.45, P=0.70), while medium- and high-CATE patients demonstrated progressively larger ADAPT advantages (aOR 2.06, 95% CI 1.67 to 2.55, and aOR 2.99, 95% CI 2.24 to 3.98, respectively, both P<0.001). Conclusions ADAPT may be superior to SR for a majority of patients, particularly in recent years, and among patients with M1 occlusions presenting in earlier time windows.
Closer Association of Liver Stiffness Than Liver Fat Content With Imaging‐Derived Neurovascular Coupling in a Metabolic Dysfunction‐Associated Steatotic Liver Disease Cohort
Jiang, Zhuoru, Chen, Futao, Fan, Zhiwen, Chen, Qian, Lu, J , Li, Weiping , Ge, Danni, Zhu, Zhengyang, Zhang, Xin, Chen, Jun, Li, Jie , Zhang, Bing , Zhang, Haitao , Li, Qi , Zhu, Zhengyang, Zhang, Xin

Mayo Clinic

Diabetes, Obesity and Metabolism | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/dom.71125 | PMID 42483871 Get It

ABSTRACT Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasingly linked to cognitive decline, yet the hepatic factors associated with imaging‐derived neurovascular coupling (NVC) remain unclear. This study aimed to investigate whether liver stiffness or liver fat content was more closely associated with resting‐state CBF‐ReHo surrogate measures. Materials and Methods A total of 130 participants including 98 MASLD patients and 32 age‐ and education‐matched healthy controls (HCs) underwent clinical assessment, neuropsychological testing, and multi‐modal MRI. Liver stiffness and fat content were quantified using MR elastography (MRE) and MRI‐proton density fat fraction (PDFF). Imaging‐derived NVC was assessed using global cerebral blood flow (CBF)‐regional homogeneity (ReHo) coupling and voxel‐wise CBF/ReHo ratios, interpreted as resting‐state surrogates rather than direct stimulus‐evoked NVC. Multivariable regression and exploratory mediation analyses were employed. Results Compared to HCs and patients with lower liver stiffness (MASLD_low), those with higher liver stiffness (MASLD_high) showed reduced global CBF‐ReHo coupling and altered CBF/ReHo ratios, primarily localized to the bilateral superior temporal pole/superior temporal gyrus (TPOsup). In multivariable regression, liver stiffness remained independently associated with TPOsup CBF/ReHo ratios ( p < 0.001). Exploratory mediation analysis showed a statistically significant indirect association between hepatocellular injury markers and TPOsup CBF/ReHo ratios involving MRE‐derived liver stiffness (95% CI: 0.0795–0.2790). Conclusions Within this cohort and the observed PDFF range, MRE‐derived liver stiffness was more closely associated with imaging‐derived NVC surrogate measures than liver fat content in MASLD. These findings are hypothesis‐generating and require validation in longitudinal studies.